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Available online 3 March 2019Background: Patients with palpitations and pre-syncope commonly present to Emergency Departments (EDs)
but underlying rhythm diagnosis is often not possible during the initial presentation. This trial compares the
symptomatic rhythm detection rate of a smartphone-based event recorder (AliveCor) alongside standard care
versus standard care alone, for participants presenting to the ED with palpitations and pre-syncope with no ob-
vious cause evident at initial consultation.
Methods: Multi-centre open label, randomised controlled trial. Participants ≥16 years old presenting to 10 UK
hospital EDs were included. Participants were randomised to either (a) intervention group; standard care plus
the use of a smartphone-based event recorder or (b) control group; standard care alone. Primary endpoint
was symptomatic rhythm detection rate at 90 days. Trial registration number NCT02783898 (ClinicalTrials.gov).
Findings: Two hundred forty-three participants were recruited over an 18-month period. A symptomatic rhythm
was detected at 90 days in 69 (n= 124; 55.6%; 95% CI 46.9–64.4%) participants in the intervention group versus
11 (n = 116; 9.5%; 95% CI 4.2–14.8) in the control group (RR 5.9, 95% CI 3.3–10.5; p b 0.0001). Mean time to
symptomatic rhythm detection in the intervention group was 9.5 days (SD 16.1, range 0–83) versus 42.9 days
(SD 16.0, range 12–66; p b 0.0001) in the control group. The commonest symptomatic rhythms detected were
sinus rhythm, sinus tachycardia and ectopic beats. A symptomatic cardiac arrhythmia was detected at 90 days
in 11 (n = 124; 8.9%; 95% CI 3.9–13.9%) participants in the intervention group versus 1 (n = 116; 0.9%; 95% CI
0.0–2.5%) in the control group (RR 10.3, 95% CI 1.3–78.5; p = 0.006).
Interpretation:Use of a smartphone-based event recorder increased the number of patients inwhom an ECGwas
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Palpitations (the noticeable pounding, ﬂuttering or irregular beating
of the heart) and pre-syncope (the sense of impending loss of conscious-
ness) are together responsible for 1% of Emergency Department (ED)
visits (300,000 annual ED attendances in the UK) [1,2]. Diagnosis of
the underlying rhythm is difﬁcult as many patients are fully recovered
by the time that they are seen in the ED. Examination and presenting
electrocardiogram (ECG) are commonly normal. Once captured, the
symptomatic rhythm underlying about 9 in 10 episodes is benign,e.g., normal sinus rhythm, sinus tachycardia or frequent ectopics
(extra or skipped heart beats) [3]. However around 1 in 10 patients do
have a cardiac arrhythmia as their symptomatic rhythm [3].
The onlyway to establish the underlying heart rhythm is to capture an
ECGwhilst the patient has symptoms.Many patients go for yearswithout
diagnosis due to the difﬁculty in capturing the underlying heart rhythm.
Recommendedﬁrst line investigationof 12-leadECG [4] and conventional
ambulatory monitoring (Holter or event monitoring) [5–6] are of limited
efﬁcacy due to the infrequency of symptoms in many patients [5,7–10].
Most patients are discharged from the ED and asked to represent or call
an ambulance should they get further symptoms in the hope of increasing
the chances of capturing the episode on a standard 12-lead ECG.
If patients are referred to cardiology services for assessment, investi-
gation usually startswith aHoltermonitor but non-compliance and lack
of extended monitoring reduces diagnostic yield to less than 20% [11].
Traditional event recorders, external continuous loop recorders and im-
plantable loop recorders are expensive and not recommended for a pa-
tient group who rarely have malignant arrhythmias and may have
prolonged periods between episodes.
Recent technological advances have led to several novel ECG moni-
toring devices appearing on the market [12,13]. The pocket sized
AliveCor (now Kardia) mobile (AliveCor, San Francisco, USA) is a mon-
itoring device that requires the patient to trigger the ECG recording
[14]. With minimal training, two ﬁngers from each hand are placed on
the monitor (which can be connected to the back of a smartphone) for
30 s to take an ECG recording, which is transmitted wirelessly to the
app, analysed and synchronised to an encrypted server. The patient
can then alert their healthcare professional to allow their ECG to be
viewed securely [14]. The device is supported for clinical use by a Na-
tional Institute for Health and Care Excellence (NICE) technology ap-
praisal [14] and was initially developed for detecting AF, for which the
automatic diagnostic algorithm has excellent sensitivity (96.6%) and
speciﬁcity (94%) for correctly interpreting AF versus normal sinus
rhythm [15]. There have been several studies investigating the use of
smartphone-based event recorders including AliveCor for population
screening for AF in various settings [16–21] and feasibility for other
rhythm disorders [3,22–24]. Whilst AliveCor has now undergone as-
sessment against conventional care for AF detection [25], it has yet to
be assessed against standard care for the broader investigation of palpi-
tations and arrhythmia assessment. There have been no studies in an
acute or ED population, where large numbers of patients present [2].
The primary aim of this study is to compare the symptomatic
rhythm detection rate at 90 days of a smartphone-based event recorder
(AliveCor) alongside standard care, compared to standard care alone,
for participants presenting to the ED with palpitations and pre-
syncope with no obvious cause evident at initial consultation.2. Methods
2.1. Design
Multi-centre open label randomised controlled trial in EDs and
Acute Medical Units (AMU) of 10 tertiary and district general hospitals
in the UK. A favourable ethical opinion was obtained from the South
East Scotland Research Ethics Committee 02 (REC reference: 16/SS/
0074) and from the HRA.
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Participants aged 16 years or over presentingwith an episode of pal-
pitations or pre-syncope and whose underlying ECG rhythm during
these episodes remains undiagnosed after ED assessment. Written con-
sent was obtained from all participants.
Table 1 shows inclusion and exclusion criteria.
3. Randomisation
Participantswere equally distributed between the two study groups.
To balance site-level characteristics and ensure investigators could not
predict the group allocation of the next-to-be enrolled patient,
randomisation was by permuted block randomisation by site. Sealed
opaque envelopes containing either ‘Standard Care plus Device’ or
‘Standard Care’ cards were prepared by a central administrator not in-
volved in the study. Blocks were randomly labelled using random num-
ber generation with site-speciﬁc study participation numbers and sent
to each local study team. Participants eligible for inclusion were
randomised by the local study team by taking the next lowest consecu-
tively numbered sealed opaque envelope.
4. Procedures
The local direct care team screened and identiﬁed potential partici-
pants using ED or the AMU triage information and clinical or electronic
records. Potentially eligible participants were assessed for study inclu-
sion by the attending clinician. If the potential participant fulﬁlled the
study eligibility criteria, they were given a Participant Information
Sheet. Afterwards, if agreeable, written consent was taken. Participants
were allocated either (a) INTERVENTION group; standard care plus the
use of a smartphone-based event recorder or (b) CONTROL group; stan-
dard care, depending on study envelope allocation. All intervention
group participants were given an AliveCor Heart Monitor and trained
in the use of the device and app in the ED or AMU by the research
team. Control group participants received no other intervention. Partic-
ipants in both groups were admitted, referred or discharged by the
treating clinician according to current local hospital protocols. Partici-
pants in both groups were followed up at 90 days through hospital re-
cord systems (paper or electronic depending on local policy), GP
records and by telephone by the local study team. Participants wereTable 1
Inclusion and exclusion criteria.
Inclusion criteria were:
1. Participant aged 16 years or over.
2. Participant presenting with an episode of palpitations or pre-syncope with no
obvious cause.
3. Participant's underlying ECG rhythm during these episodes remains undiag-
nosed after clinical assessment.
Exclusion criteria were:
1. Prior diagnostic ECG.
2. Palpitations or pre-syncope present during an admission ECG.
3. Frequent episodes (i.e. at least once a day).
4. Participants under 16 years of age.
5. Previous participation in the study.
6. Alcohol/illicit drugs/seizure/stroke/transient ischaemic attack/head trauma/-
hypoglycaemia as presumptive cause.
7. Inability or unwilling to give informed consent.
8. Participants with recent (i.e., within 3 months) myocardial infarction, severe
heart failure (New York Heart Association class 4) or unstable angina.
9. Participants unwilling or unable to use the AliveCor Heart Monitor and
AliveECG app.
10. Participants without a compatible smartphone or tablet.
11. Participants with cardiac pacemakers or other implanted electronic devices.
12. No telephone number for follow-up.
13. Participant in custody.also asked to complete a standardised written questionnaire. They
also received a follow-up telephone call from the local study team
enquiring about symptoms and contact with medical services. Partici-
pants were also asked about satisfaction and compliance.
If a participant allocated to the intervention group had an episode of
palpitations or pre-syncope and was able to record an AliveCor Heart
Monitor ECG during the episode, the participant emailed the ECG at a
convenient time to the secure (nhs.net) email address of the coordinat-
ing Edinburgh research team. This email included a Portable Document
Format (pdf) ﬁle attachment of the ECG tracing along with the
participant's AliveCor app login (which was their study number; no
identiﬁable participant data left the local site).
The AliveCor app rhythm analysis algorithm automatically reported
any ECG recorded as Normal, Atrial Fibrillation or Unclassiﬁed. The duty
Consultant Emergency Physician at the coordinating Edinburgh centre
alongwith a trial teamEmergency Physician reviewed theECG. The cen-
tral study team contacted the local study team to arrange follow-up if
required. In cases of disagreement, the central cardiology team were
contacted for further opinion.
If specialist follow-up of the ECG tracing was not required, the local
study team wrote to the participant informing them and asked them
to arrange follow-up with their general practitioner (GP) who was
also contacted with the report. Participants continued to record ECGs
for the duration of the study period, but the participant and GP were
not contacted again if participants recorded further ECGs that similarly
did not require specialist follow-up.
If the participant's ECG recorded a serious cardiac arrhythmia, i.e.,
• ventricular tachyarrhythmia
• complete or 3rd degree heart block
• second degree heart block type II (assumed to be symptomatic given
the participant had chosen to record an ECG during the episode)
• pause N6 s
• symptomatic bradycardia b40 beats/min
during the study period, the central study team contacted the local
study team who alerted the participant immediately by telephone,
and referred them urgently to their local ED or cardiac electrophysiol-
ogy service (as per local protocol).
Participantswere asked to use a participant symptomdiary to record
any symptoms and include time and date, type of symptom and
whether they were able to record an ECG during the symptoms. They
returned this diary to the local study team along with the participant
satisfaction and compliance questionnaire, and smartphone-based
event recorder at the end of the 90 days in a pre-paid stamped, ad-
dressed envelope. Participants failing to do this were reminded by
phone. Participant study information identiﬁed by study number
alone, was collected on a paper Case Report Form and then entered
into a specially designed password protected online accessed secure da-
tabase (REDCAP; http://www.project-redcap.org), the server of which
was held within the University of Edinburgh. The primary outcome
was assessed by each local study team.
5. Outcomes
5.1. Primary Outcome
1. Symptomatic rhythmdetection rate of a smartphone-based event re-
corder for symptomatic rhythm detection at 90 days versus standard
care.
A ‘symptomatic rhythm’will be any ECG rhythm recorded during an
episode of palpitations or pre-syncope allowing symptom–rhythm cor-
relation. This can be either via the AliveCor Heart Monitor ECG or
through standard care.
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Fig. 1. Study recruitment diagram.
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Table 2
Baseline characteristics of study population.
Data are n (%) unless stated. N = 242 (125/117) unless stated. Different denominators due to missing data
Intervention
n = 125
Control
n = 117
Total
n = 242
Gender: Male 51 40.8 54 46.2 105 43.4
Age in years/mean (SD) 40.0 (14.0) 39.1 (13.5) 39.6 (13.8)
Number of episodes palpitations or pre-syncope in last 24 h/median (IQR) 1.0 (1.0–3.0) 1.0 (1.0–3.0) 1.0 (1.0–3.0)
History of presenting episode
Palpitations 110 88.0 109 93.2 219 90.5
Pre-syncope 15 12.0 8 6.8 23 9.5
Estimated length of presenting (last) episode
1 min or less 19 15.2 19 16.2 38 15.7
10 min or less 31 24.8 37 31.6 68 28.1
1 h or less 27 21.6 27 23.1 54 22.3
More than 1 h 48 38.4 34 29.1 82 33.9
Participants description of symptoms
Anxious 52 41.6 50 42.7 102 42.1
Arm or neck pain or tingling 34 27.2 33 28.2 67 27.7
Chest pain or pressure 51 40.8 52 44.4 103 42.6
Dizziness 62 49.6 56 47.9 118 48.8
Faint/Light headed 73 58.4 61 52.1 134 55.4
Pounding 55 44.0 56 47.9 111 45.9
Fluttering 42 33.6 38 32.5 80 33.1
Short of breath 51 40.8 49 41.9 100 41.3
Fast/Racing heart 77 61.6 68 58.1 145 59.9
Skipped/missed heartbeat(s) 33 26.4 27 23.1 60 24.8
Irregular heart beating 36 28.8 40 34.2 76 31.4
How often do they occur?
Never had before
29
(n = 124)
23.4 29 24.8
58
(n = 241)
24.1
Yearly (or even less frequent)
21
(n = 124)
16.9 27 23.1
48
(n = 241)
19.9
Monthly
27
(n = 124)
21.8 25 21.4
52
(n = 241)
21.6
Weekly
18
(n = 124)
14.5 15 12.8
33
(n = 241)
13.7
More than once a week
29
(n = 124)
23.4 21 17.9
50
(n = 241)
20.7
How do the palpitations start?
Suddenly
104
(n = 123)
84.6 94/116 81.0
198
(n = 239)
82.8
Gradually
19
(n = 123)
15.4 22/116 19.0
41
(n = 239)
17.2
Can palpitations be provoked? Yes
16
(n = 123)
13.0
18
(n = 116)
15.5
34
(n = 239)
14.2
How do the palpitations end?
Suddenly
48
(n = 121)
39.7
47
(n = 115)
40.9
95
(n = 236)
40.3
Gradually
73
(n = 121)
60.3
68
(n = 115)
59.1
141
(n = 236)
59.7
Participant able to end the attacks? Yes
19
(n = 123)
15.4 14 12.0
33
(n = 240)
13.8
Recent alcohol use? Yes 11 8.8 16 13.7 27 11.2
Recent cocaine or amphetamine use? Yes 1 0.8 0 0.0 1 0.4
Recent (last 7 days) febrile illness? Yes 9 7.2 8 6.8 17 7.0
Past medical history
Previous or known hypertension/ischaemic/coronary/valvular heart disease/failure Yes
14
(n = 124)
11.3 20 17.1
34
(n = 241)
14.1
Previous or known anaemia or thyrotoxicosis Yes
4
(n = 124)
3.2 3 2.6
7
(n = 241)
2.9
Drug history – is the patient taking
β agonists Yes 7 5.6 8 6.8 15 6.2
Antimuscarinics/Anticholinergic Yes 5 4.0 2 1.7 7 2.9
Theophylline Yes 0 0.0 1 0.9 1 0.4
Dihydropyridine calcium channel blockers Yes 3 2.4 6 5.1 9 3.7
Class 1 anti-arrhythmics Yes 1 0.8 2 1.7 3 1.2
Drugs that may prolong the QT interval Yes 1 0.8 0 0.0 1 0.4
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1. Symptomatic rhythm detection rate of a smartphone-based event re-
corder for cardiac arrhythmia detection at 90days versus standard care.
2. Time to detection of symptomatic rhythmusing a smartphone-based
event recorder versus standard care.
3. Time to detection of symptomatic cardiac arrhythmia (rhythm that
is not sinus rhythm/sinus tachycardia/ectopic beats) using a
smartphone-based event recorder versus standard care.4. Number of participants treated or (planned for treatment) for cardiac
arrhythmia in participants using a smartphone-based event recorder
versus standard care.
5. Participant satisfaction and monitor compliance.
6. Cost-effectiveness analysis.
7. Serious outcomes at 90 days: all cause death and major adverse car-
diac events [MACE] (myocardial infarction, life-threatening arrhyth-
mia, insertion of a pacemaker or internal cardiac deﬁbrillator,
insertion of pacing wire).
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Serious outcomes were routinely collected as part of the study. The
only adverse events recorded were those directly related to the use of
the smartphone-based event recorder and application.
5.4. Statistical Methods
5.4.1. Sample Size
Using a symptomatic rhythm detection rate at 90 days of 25% [4]
versus standard care (10%), we estimated that 110 participants in
each group would have 80% power to determine an absolute 15 per-
centage point improvement in symptomatic rhythm detection. We
aimed to recruit an extra 10% in each group to allow for drop out
(i.e., 121 participants in each group).
5.4.2. Analysis
Descriptive analysis of participants are presented split by allocated
study group. Baseline to 90-day change in diagnostic yield between
the two study groups was analysed using comparison of proportionsTable 3
Examination ﬁndings, initial ECG and management.
Data are n (%) unless stated. N = 242 (125/117) unless stated. Different denominators du
Interv
n = 1
Examination
Initial pulse at triage /bpm - mean (SD)
Initial systolic BP at triage /mmHg - mean (SD)
Initial diastolic BP at triage /mmHg - mean (SD)
First postural difference if present /mmHg - mean (SD)
Admission ECG
Rate /bpm - mean (SD)
QRS axis - median (IQR)
7
QTc int /ms - mean (SD)
Sinus rhythm
PR N 200 ms
Slow risk in the initial portion of the QRS
Heart block?
QRS duration ≥ 120 ms 2 (n
Number of ventricular ectopics
0 118 (
1 4 (n
2 2 (n
ED clinician rating of likelihood of any underlying cardiac arrhythmia
1 14 (n
2 18 (n
3 15 (n
4 15 (n
5 19 (n
6 13 (n
7 14 (n
8 10 (n
9 3 (n
10 0 (n
Management
Participant discharged from the ED/AMU
Participant referred to outpatients 15 (n
If admitted then where?
Ward - Non monitored 3 (
Ward - Monitored 0 (
Coronary Care Unit 2 (
Direct to cardiology ward 3 (
Reason(s) for admission?
Palpitation/pre-syncope investigation 8 (
Other 0 (tests. Additional comparison of proportions tests were used to compare
further categorical binary variables between study groups (where ex-
pected countswere small the p-value from the Fisher's testwas used in-
stead). Categorical variables were compared using a χ2 test (and χ2 test
for trend if appropriate). Log-rank tests and Kaplan–Meier curves were
used to examine if the smartphone recorder had an effect on the time to
detection of symptomatic rhythm and symptomatic cardiac arrhythmia
separately up to 90 days versus standard care. All participants were
analysed on an intention to treat basis. Statistical signiﬁcancewas deter-
mined as p b 0.05 for all outcomes with an acknowledgment of in-
creased type I error risk in the secondary outcomes not considered in
the power calculation.
5.4.2.1. Economic Analysis. Overall and median healthcare utilisation
costs (primary/community/secondary care and intervention costs)
were calculated for both groups. The costing scope included primary
care, secondary care and community NHS costs obtained from 2016/
17 NHS reference cost data. AMann–Whitney test was used to examine
the overall cost-effectiveness between the smartphone-based event re-
corder and standard care. Healthcare utilisation costs per symptomatice to missing data
ention
25
Control
n = 117
Total
n = 242
85.3 (19.4)
(n = 124)
83.0 (15.2)
(n = 116)
84.2 (17.5)
(n = 240)
139.0 (22.5)
(n = 124)
139.0 (20.5)
(n = 116)
139.0 (21.5)
(n = 240)
83.8 (12.7)
(n = 124)
84.1 (13.6)
(n = 116)
83.9 (13.1)
(n = 240)
6.7 (7.6)
(n = 7)
0.3 (0.8)
(n = 6)
3.8 (6.3)
(n = 13)
78.8 (18.8) 77.5 (16.1) 78.2 (17.5)
9.0 (39.0–88.0)
(n = 117)
80.0 (42.0–90.0)
(n = 107)
79.5 (40.5–89.0)
(n = 224)
395.1 (86.7)
(n = 125)
401.5 (47.3)
(n = 114)
398.2 (70.6)
(n = 239)
123 98.4 117 100.0 240 99.2
7 5.6 4 3.4 11 4.5
0 0.0 0 0.0 0 0.0
0 0.0 0 0.0 0 0.0
= 124) 1.6 3 (n = 116) 2.6 5 (n = 240) 2.1
n = 124) 95.2 115 (n = 116) 99.1 233 (n = 240) 97.1
= 124) 3.2 1 (n = 116) 0.9 5 (n = 240) 2.1
= 124) 1.6 0 (n = 116) 0.0 2 (n = 240) 0.8
= 121) 11.6 23 (n = 116) 19.8 37 (n = 237) 15.6
= 121) 14.9 12 (n = 116) 10.3 30 (n = 237) 12.7
= 121) 12.4 18 (n = 116) 15.5 33 (n = 237) 13.9
= 121) 12.4 17 (n = 116) 14.7 32 (n = 237) 13.9
= 121) 15.7 13 (n = 116) 11.2 32 (n = 237) 13.9
= 121) 10.7 14 (n = 116) 12.1 27 (n = 237) 11.4
= 121) 11.6 6 (n = 116) 5.2 20 (n = 237) 8.4
= 121) 8.3 8 (n = 116) 6.9 18 (n = 237) 7.6
= 121) 2.5 4 (n = 116) 3.4 7 (n = 237) 3.0
= 121) 0.0 1 (n = 116) 0.9 1 (n = 237) 0.4
117 93.6 114 97.4 231 95.5
= 116) 12.9 15 (n = 114) 13.2 30 (n = 230) 13.0
n = 8) 37.5 2 (n = 3) 66.7 5 (n = 11) 45.5
n = 8) 0.0 0 (n = 3) 0.0 0 (n = 3) 0.0
n = 8) 25.0 1 (n = 3) 33.3 3 (n = 11) 27.3
n = 8) 37.5 0 (n = 3) 0.0 3 (n = 11) 27.3
n = 8) 100.0 2 (n = 3) 66.7 10 (n = 11) 90.9
n = 8) 0.0 1 (n = 3) 33.3 1 (n = 11) 9.1
43M.J. Reed et al. / EClinicalMedicine 8 (2019) 37–46rhythm diagnosis were calculated for both groups using overall
healthcare utilisation cost and number of patients with a symptomatic
rhythm in each group.
Analyses were performed in SAS 9.4 (SAS Institute, Cary NC). The
sponsor deemed that a data monitoring committee was not required.
This trial was registered at ClinicalTrials.gov (trial registration number
NCT02783898), and the protocol published in Trials [26].
6. Results
Between 4 July 2016 and 9 January 2018, 243 participants were re-
cruited to the study at 10 centres (Edinburgh 66 participants, 27.2%,
Reading 57, 23.5%, Royal London 43, 17.7%, Exeter 24, 9.9%, Plymouth
15, 6.2%, Chesterﬁeld 12, 4.9%, Leicester 12, 4.9%, Musgrove Park 5,
2.1%, Nottingham 5, 2.1%, Whipps Cross 4, 1.6%). Fig. 1 details the
study recruitment diagram, and Table 2 details the baseline characteris-
tics of enrolled participants. One hundred twenty-six participants were
allocated to the intervention group and 117 to the control group. Two
hundred nineteen (90.5%) participants presented with palpitations
and 23 (9.5%) with pre-syncope. One participant was removed from
the study by the local study team after being randomised, as they did
not meet the inclusion criteria. Baseline data were therefore collected
on 125 participants in the intervention group and 117 in the control
group. Participants ranged from 17 to 74 years of age with a mean age
of 39.5 (SD 13.7). Table 3 details examination ﬁndings, initial ECG and
management. One participant in each group was lost to follow-up leav-
ing 124 participants available for analysis in the study group and 116 in
the control group.
A symptomatic rhythm was detected at 90 days in 69 (n = 124;
55.6%; 95% CI 46.9–64.4%) participants in the intervention group versus
11 (n= 116; 9.5%; 95% CI 4.2–14.8) in the control group (RR 5.9, 95% CI
3.3–10.5; p b 0.0001). A symptomatic cardiac arrhythmia was detected
at 90 days in 11 (n = 124; 8.9%; 95% CI 3.9–13.9%) participants in the
intervention group versus 1 (n=116; 0.9%; 95% CI 0.0–2.5%) in the con-
trol group (RR 10.3, 95% CI 1.3–78.5; p = 0.006).
Themean time to symptomatic rhythmdetection in the intervention
group was 9.5 days (SD 16.1, range 0–83) versus 42.9 days (SD 16.0,
range 12–66) in the standard care group (p b 0.0001). Fig. 2 showsFig. 2. Kaplan–Meier curve showing number of participants undiagnosethe Kaplan–Meier curve of proportion of participants undiagnosed ver-
sus time up to 90 days for the intervention and control groups.
Commonest symptomatic rhythms detected were sinus rhythm (in 53
participants; 66.3%), sinus tachycardia (19; 23.8%) and ectopic beats
(13; 16.3%). Someparticipants hadmore than one symptomatic rhythm
recorded. Eighty participants had a symptomatic rhythm detected with
12 of these having a symptomatic cardiac arrhythmia (atrial ﬁbrillation
or ﬂutter, SVT and sinus bradycardia) and 68 having sinus rhythm, sinus
tachycardia or ectopics [Table 4]. There were four cases where the cen-
tral cardiology teamwere required for further ECG opinion after review
by both the central on call and trial team Emergency Physicians. Table 4
also details how the diagnosis was made in both groups.
The mean time to symptomatic cardiac arrhythmia detection in the
intervention group was 9.9 days (SD 15.6, range 1–55) versus
48.0 days (1 participant) in the control group (p = 0.0004). Symptom-
atic cardiac arrhythmias were AF (8 intervention, 0 standard care), SVT
(3 intervention, 0 standard care), sinus bradycardia (0 intervention, 1
standard care) and atrial ﬂutter (1 intervention, 0 standard care).
Serious outcome at 90 days in the intervention group was 11 (8.9%)
versus 2 (1.7%) in the control group (p = 0.02). At 90 days, 12 partici-
pants in the intervention group were subsequently undergoing (or
planning to undergo) treatment for symptomatic cardiac arrhythmia
versus 6 in the control group (p = 0.192). Table 5 details the results
of the participant satisfaction and monitor compliance questionnaire.
Eighty of 92 (87.0%) participants found the AliveCor monitor easy to
use. There were more ED presentations (after index visit) due to
palpitations/pre-syncope in the intervention group (12/124; 9.7%; 95%
CI 4.5–14.9% with 1 or more non index ED presentations) compared to
the control group (3/116; 2.6%; 95% CI 0.0–5.5%; p = 0.031). The only
death in the study was in the intervention group in a participant
known to have treated congenital structural heart disease whose
death was thought unrelated to his initial presentation to the ED.
There was no difference in the number of participants with one or
more inpatient hospital days (over all admissions) due to palpitations
or pre-syncope in the intervention group (2; n = 122; 2 patients with
no data; 1.6%; 95% CI 0.0–3.8%) compared to the control group (1; n
= 116; 0.9%; 95% CI 0.0–2.5%; p N 0.999), number of outpatient presen-
tations due to palpitations or pre-syncope (p = 0.058), number of GPd (y axis) versus time up to 90 days (x axis) in both study groups.
Table 4
Summary of symptomatic rhythms, symptomatic cardiac arrhythmias and serious
outcomes.
N = 240 (124/116) unless stated. Different denominators due to missing data
*some participants had more than one symptomatic rhythm recorded
Intervention
n = 124
Control
n = 116
Total
n = 240
Symptomatic rhythm*
69
(55.6%)
11
(9.5%)
80
(33.3%)
Sinus rhythm (40–100) 48 5 53
Sinus tachycardia (N100) 12 7 19
Ectopics 8 5 13
Atrial ﬁbrillation 8 0 8
SVT 3 0 3
Atrial ﬂutter 1 0 1
Sinus bradycardia (b40) 0 1 1
Atrial tachycardia 0 0 0
Ventricular tachycardia 0 0 0
Other rhythm 1 2 3
Method of diagnosis of symptomatic
rhythm*
AliveCor 65 0 65
24-hour Holter 2 5 7
48-hour Holter 1 2 3
7+ day Holter 0 1 1
Subsequent ED visit ECG 2 1 3
GP visit ECG 0 2 2
Symptomatic cardiac arrhythmia*
11
(8.9%)
1
(0.9%)
12
(5.0%)
Atrial ﬁbrillation 8 0 8
SVT 3 0 3
Sinus bradycardia (b40) 0 1 1
Atrial ﬂutter 1 0 1
Serious outcome*
11
(8.9%)
2
(1.7%)
13
(5.4%)
All cause death 0 1 1
Major adverse cardiac events
[MACE = myocardial infarction,
life-threatening arrhythmia,
insertion of a pacemaker or internal cardiac
deﬁbrillator, insertion of pacing wire]
0 1 1
Cardiac arrhythmia 11 1 12
Signiﬁcant structural heart disease 0 1 1
Initiation of anti-arrhythmia medical therapy 1 0 1
Life-threatening arrhythmia
[ventricular tachyarrhythmia, complete or 3rd
degree heart block,
second degree heart block type II, pause N6 s,
symptomatic bradycardia b40 beats per
minute]
0 0 1
Table 5
Results of the participant satisfaction and monitor compliance questionnaire.
Intervention arm
N %
Total 125 100.0
The AliveCor heart monitor was
easy to use
Missing 33 26.4
Strongly Disagree 4 3.2
Disagree 0 0
Neutral 8 6.4
Agree 32 25.6
Strongly Agree 48 38.4
The AliveCor heart monitor was
always available when I had
symptoms and needed to record
my heart tracing
Missing 34 27.2
Strongly Disagree 2 1.6
Disagree 9 7.2
Neutral 14 11.2
Agree 27 21.6
Strongly Agree 39 31.2
I had no problems recording a
heart tracing using the AliveCor
app
Missing 34 27.2
Strongly Disagree 3 2.4
Disagree 5 4.0
Neutral 16 12.8
Agree 26 20.8
Strongly Agree 41 32.8
I had no problems sending a heart
tracing to the study team using
the AliveCor app
Missing 34 27.2
Strongly Disagree 2 1.6
Disagree 5 4.0
Neutral 25 20.0
Agree 24 19.2
Strongly Agree 35 28.0
During the study period (3
months) I was able to record a
heart tracing when I had similar
symptoms to the time I initially
visited the Emergency
Department
Missing 34 27.2
Strongly Disagree 2 1.6
Disagree 8 6.4
Neutral 27 21.6
Agree 28 22.4
Strongly Agree 26 20.8
The AliveCor heart monitor will be
useful in diagnosing the cause of
my symptoms
Missing 34 27.2
Strongly Disagree 1 0.8
Disagree 6 4.8
Neutral 33 26.4
Agree 24 19.2
Strongly Agree 27 21.6
Had you ever used a mobile heart
tracing device before
Missing 32 25.6
Yes 5 4.0
No 88 70.4
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ber of ECGs performed due to palpitations or pre-syncope (p =
0.143). Median overall healthcare utilisation cost (primary/commu-
nity/secondary care and intervention costs) in the intervention group
was £108 (IQR 99.0–246.50, range 99–2697) versus £0 in the standard
care group (IQR 0–120.0, range 0–4161; p = 0.0001). Cost per symp-
tomatic rhythm diagnosis was £921 less per patient per symptomatic
rhythm in the intervention group (£474) compared to the control
group (£1395).
7. Discussion
Use of a smartphone-based event recorder increases the symptom–
rhythm correlation rate over ﬁve-fold at 90 dayswith a reduced cost per
diagnosis. These are clinically signiﬁcant rhythms as they diagnose the
underlying cause of the patient's symptoms. In patients presenting
with palpitations or near syncope the incorporation of a patient-
activated detection device into routine practice may overcome some
of the current difﬁculties in diagnosis caused by the normalisation of
cardiac rhythm by the time the patient undergoes a clinical assessment.
Given the frequency of patients presenting to the ED with palpitations
and pre-syncope, our study ﬁndings suggest that a smartphone-basedevent recorder should be considered as part of on-going care of all pa-
tients presenting acutely with these symptoms.
There are different potential ways of incorporating the technology
into patient care, which may depend on the conﬁguration of local
healthcare systems. In this study the devices and instructions were
given to patients in the ED by a researcher, but this could also be under-
taken at a follow-up appointmentwith a specialist nurse or family prac-
titioner, where there is less time pressure than in emergency care. In
this study, the ECGs were transmitted for central analysis; however,
an alternative approach may be for the patient to show, on their
phone, any recorded ECGs at a follow-up appointment. This would re-
move the need for the transfer of sensitive patient data and mean that
a clinical system to respond to emailed ECGs would not be required.
The AliveCor app rhythm analysis algorithm automatically reports any
ECG recorded as normal, atrial ﬁbrillation or unclassiﬁed with excellent
sensitivity and speciﬁcity. Features such as this that are also found in
other devices such as the newly launched Apple Watch Series 4 should
allow ECG interpretation and patient education to be delivered at the
time of ECG recording thereby reducing demand on physicians.
More patients had a subsequent ED attendance in the intervention
group compared the control group. Whilst this number is small, it may
be that the remote transmission of an ECG did not give the patient the
immediate reassurance that they required. The psychology of patient in-
teractionwith ‘smart’ personalmedical devices is an emergingﬁeld, and
better understanding of patient/device interaction is likely to be impor-
tant in realising the potential beneﬁts of new technologies.
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previous work in ED patients which showed that 74% found it accept-
able to use a smartphone to monitor their health, 79% to use a medical
device connecting to a smartphone to monitor their health, and 77% re-
ported that theywould feel conﬁdent to use such technology [27]. There
is a concern that self-monitoring may lead to increased anxiety; how-
ever when the Arrhythmia Alliance [14] distributed AliveCor Heart
Monitors to 1500 people of all ages, only one returned their monitor be-
cause it caused them to worry and check their heart rate too often.
We found that the commonest reason for a patient not to be able to
participate was that they did not possess a smartphone. We did not re-
cord the age of non-participants, but it is likely that thesewere older pa-
tients. However, whilst smartphone ownership decreases with age our
previous research shows 64% of those aged 50–75 and 30% over
75 years of age own a smartphone [27], and in the Arrhythmia Alliance
study, older people were noted to be regular users of mobile technology
and gave positive feedback about the system [14].
This study conﬁrms previous evidence that most symptomatic
rhythms in patients with palpitations or pre-syncope are benign [28].
Only 12 of 240 participants in the study experienced a symptomatic car-
diac arrhythmia; the remaining 68 with symptomatic palpitations or
pre-syncope were found to have sinus rhythm, sinus tachycardia or ec-
topic beats. Even in the absence of underlying arrhythmia, previously
unexplained symptoms can cause anxiety and can have a signiﬁcant im-
pact on quality of life [29]. With such a low incidence of cardiac diagno-
ses in this population, it is perhaps appropriate that follow-up of these
patients is in community care rather than in cardiology clinics (where
currently these conditions account for up to one-ﬁfth of all referrals)
[30–33], with only patients diagnosed with a symptomatic cardiac ar-
rhythmia being referred to specialist care.
This study suggests that the AliveCor technology performs effec-
tively and safely. The randomised, prospective design with systematic
data collection is a key strength of the study. Whilst there was a poten-
tial variation in standard care between sites, this element of pragmatic
design ensures our ﬁndings are generalisable across all types of stan-
dard care in the UK National Health Service without compromising va-
lidity. Potential limitations of our study include a large proportion of
recruitment occurring in ofﬁce hours largely by research staff in re-
search active hospitals and the use of a central ECG reading service
not available in routine practice.
Only one type of device was studied and many similar devices are
entering the market. We think that the results of this study will be
generalisable across many forms of patient-activated, symptom-based
home ECG recording devices. Subtle differences in design or incorpora-
tion into clinical workﬂow may have an inﬂuence on effectiveness, so
novel devices should undergo clinical evaluation. It is also possible
that patients choosing to take part in a study of new technology may
be more motivated to use the device, and it may not perform as well
in a non-study setting.
In summary, this study demonstrates the ability of a smartphone-
based event recorder to improve clinical care and patient experience
for those suffering undiagnosed palpitations and pre-syncope. These
ﬁndings are likely to be generalisable fromEmergencyMedicine toGen-
eral/Internal/Acute Medicine and General (Family) Practice in a broad
range of developed healthcare systems. A safe, non-invasive and easy
to use smartphone-based event recorder should be considered part of
on-going care of all patients presenting acutely with unexplained palpi-
tations or pre-syncope.
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